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Metabolic Crosstalk
in Heart Failure
New Roles for
B-Type Natriuretic Peptide*
Heinrich Taegtmeyer, MD, DPHIL
Houston, Texas
The discovery of natriuretic peptides by de Bold et al. (1)
has established the heart as an endocrine organ and spawned
the development of B-type natriuretic peptides (BNPs) as
biomarkers for the detection and progression of heart failure
(2). It has also spawned the clinical development and
marketing of the recombinant human BNP nesiritide for
the treatment of decompensated heart failure (3). Although
much still remains to be learned about the systemic action of
natriuretic peptides (4), several mechanisms have linked
them to plasma volume regulation through the regulation of
the body’s sodium and water balance (5). Who would have
thought that natriuretic peptides have lipolytic properties
independent of cyclic adenosine monophosphate production
(6)? Nonetheless, these lipolytic properties bring BNPs into
the league of hormones like norepinephrine and adrenaline
(lipolytic) and insulin (antilipolytic).
See page 1119
The study by Polak et al. (7) in this issue of the Journal
provides an exciting new aspect to this paradigm (Fig. 1).
The authors used an elegant microdialysis technique to
monitor glycerol release and, indirectly, the release of fatty
acids from intracellular triglycerides (8) to show that active
BNP1–32 induces lipolysis (Fig. 1A). However, in chronic
eart failure, BNP is either converted to its inactive form
esulting in a lower ratio of BNP1-32 to total immunoreac-
ive BNP (iBNP) or degraded and replaced by its inactive
orm (Fig. 1B), lacking the lipolytic effects of BNP1–32.
Consequently, the heart should be exposed less to the
deleterious effects of fatty acid levels, which are a major
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(10), and the pathogenesis of heart failure (11).
The sequence may be summarized as follows: In response
to BNP, there is increased triglyceride breakdown in adi-
pocytes (Fig. 1A), which increases the levels of free fatty
acids in the bloodstream. Increased fatty acid concentrations
in the plasma, in turn, increase fatty acid uptake by the heart
(12), resulting in decreased cardiac efficiency compared with
carbohydrate substrates (13).
Even in today’s era of molecular sophistication, it is
difficult not to be in awe of the wisdom of the body to
protect the heart from the ravages of dysregulated metabo-
lism of energy-providing substrates. A few sentences on
systemic metabolism and its effects on cardiac function may
help in realizing the importance of the study. Work per-
formed by Richard Bing (14) more than half a century ago
has firmly established that the human heart derives its
energy for contraction by the oxidation of fat and, to a lesser
extent, of carbohydrates. Compared with fatty acid and
triglyceride levels, glucose levels are tightly regulated in the
circulation. Although the interaction of those substrates
continues to be a subject of active research, it is clear that, on
a beat-to-beat basis, the heart takes up exactly the amount
of fuel needed for its pump function. Flooding the heart
with fuel would be akin to flooding an engine with gasoline.
The engine will choke. The heart probably functions best
when it oxidizes 2 types of fuels, fatty acids and carbohy-
drates, at the same time (15), but there is also a remarkable
flexibility of the heart’s metabolism response to its metabolic
and physiological environment. No wonder, then, that most
cardiologists consider cardiac metabolism as something that
is always there or as something that is too complicated and
not necessary to deal with in detail (16). The whole system
is geared toward survival—survival of the heart and with it
survival of the whole organism. Myocardial ischemia is the
notable exception.
This is not the place to delve into the intricacies of
metabolic fluxes in highly integrated and highly regulated
systems like the human body and the heart. In his celebrated
paper “Starvation in Man,” George Cahill (17) makes the
point that with fasting, adipose triglyceride breakdown
promotes gluconeogenesis and results in 3 patterns of fuel
use: terminal glucose combustion (in the brain), glycolysis
(in red blood cells), and the use of fatty acids and ketone
bodies in the rest of the body. Enhanced use of fatty acids
gives rise to insulin resistance in the heart, impaired Krebs
cycle flux, and the ensuing accumulation of nonoxidative
fatty acid metabolites (18). The consequence is lipotoxic
stress and cell death culminating in heart failure (19).
The intriguing findings of the present study are that here
may be a protective mechanism that breaks the flooding of the
heart with excess fuel. However, this can only be a speculative
conclusion. The superb study leaves several key issues open.
First, the authors did not measure circulating fatty acid levels in
response to BNP infusion. Second, cardiac function was also
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circulating hormones, cytokines, and metabolites were not
assessed. There are additional confounders such as different
etiologies of heart failure (ischemic and nonischemic), medi-
cations, and duration of symptoms. Nonetheless, the results of
this study take heart failure research into the realm of systemic
metabolism and the efficiency of fuel supply for the heart. Like
the discovery of natriuretic peptides in the heart 30 years ago,
the interplay of physiology and biochemistry continues to be
full of surprises.
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